● PRNewsWireNov 16, 2026 · 01:57 ETCOMPANY'S OWN WORDS
Evotec Secures $2.9 Million Grant to Advance Early Drug Safety Testing Using Human Stem Cell Technology
New three-year grant from the Gates Foundation extends a 2023 project to help global health researchers predict potential fetal development risks posed by novel drug candidates Evotec's human stem cell-based platform ena…
● PRNewsWireNov 5, 2026 · 02:18 ETCOMPANY'S OWN WORDS
Evotec Reports Third Quarter and Nine-Month 2026 Results: Building Growth Momentum Toward 2030 Goals
Financial performance: Q3 and nine-month Group revenue of €164.9 m and €465.0 m, respectively (Q3: €164.2 m, 9M: €477.4 m at CER); adj. Group EBITDA of -€1.6 m and -€44.3 m, respectively (Q3: -€1.7 m, 9M: -€39.1 m at CER…
● PRNewsWireOct 29, 2026 · 03:00 ETCOMPANY'S OWN WORDS
Evotec SE to Announce Results for the First Nine Months 2026 on November 5, 2026
HAMBURG, Germany, Oct. 29, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) will hold a webcast and conference call to announce its financial results for the first nine months 2026 and provide…
● PRNewsWireOct 15, 2026 · 02:04 ETCOMPANY'S OWN WORDS
Evotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board
Will lead Evotec's global scientific strategy and drive differentiation across its discovery and development services, technology platforms and proprietary innovation Brings more than 25 years of global experience in pha…
Evotec (NASDAQ:EVO) Sees Unusually-High Trading Volume – Time to Buy?
Evotec AG (NASDAQ: EVO - Get Free Report) saw unusually-strong trading volume on Monday. 143,696 shares traded hands during mid-day trading, an increase of 43% from the previous session's volume of 100,289 shares. The st…
Dr. Cord Dohrmann to step down as of September 30, 2026 Search ongoing for a successor HAMBURG, Germany, Sept. 29, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that Chief S…
Evotec: The Market Seems Split On The Company's Prospects, Buy
Evotec faces deteriorating fundamentals, with 1H26 revenue down nearly 20% and adjusted EBITDA turning sharply negative. I have withdrawn confidence in management's targets; valuation is now strictly on an as-is basis, w…
Just - Evotec Biologics Advances U.S. Department of War Antibodies Against Orthopoxvirus into Phase 1 Clinical Studies
First-in-human Phase 1 study initiated for investigational antibodies targeting orthopoxviruses developed under U.S. Department of War Accelerated Antibodies Program Supports development of countermeasures against orthop…
Kept in their own lane. A press release is the company talking, not reporting.
Tied to events
No upcoming events in the feeds.
Most covered today
Quiet tape today.
The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.